CRISPR market

pharma-news-for-takeda-ac-immune-eli-lilly-bristol-myers-squibb

May 14, 2024

Takeda and AC Immune’s Alzheimer’s Deal; Eli Lilly’s Donanemab FDA Review; Bristol Myers Squibb’s Phase III CheckMate -73L Trial Result; Regeneron Pharmaceuticals’ Dupixent sBLA; Excision BioTherapeutics’ EBT-101 Phase I/II Trial Results

crispr-technology-market

Jun 10, 2022

Unraveling the Potential of CRISPR Technology in the Gene-editing Space

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper